Effect of Consumption of Yogurt Fortified in Calcium and Vit. D on Circulating Levels of 25OHD in Postmenopausal Women
NCT ID: NCT02534064
Last Updated: 2015-10-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
140 participants
INTERVENTIONAL
2014-10-31
2015-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Investigation of Vitamin D3 Enriched, Reduced-fat Yellow Cheese Efficacy to Prevent Vitamin D Deficiency
NCT02543671
Comparison of Efficacy of Vitamin D and Vitamin D-calcium Fortified Yogurt Drink in Diabetic Patients
NCT01229891
Vitamin D Supplementation in Postmenopausal Women With Osteoporosis: Proposal of a Therapeutic Regimen in Practice
NCT02518763
Effect of Vitamin D Oral Supplements on 25 OH Vitamin D Levels
NCT01170494
Vitamin D Receptor Polymorphisms and Efficacy of Vitamin D-Fortified Yogurt Drink in Patients With Type 2 Diabetes
NCT01236846
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The current recommendation for vitamin D intake is 20 µg per day for adults (19-50 yo) and between 25 and 37.5 µg per day for people over 50 years old according to the French National Medicine Academy. However, the recommended daily allowance (RDA) in France for vitamin D is limited to 5 µg corresponding to the maximum enrichment allowed in a food product. The current study is designed to evaluate if a daily consumption of two CALIN+ yogurts enriched with 5µg of vitamin D is sufficient to improve the vitamin D status in postmenopausal women.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A: 2 yogurts
consumption of 2 CALIN+ pots per day during 16 weeks and follow up without product intake during 8 weeks.
CALIN+
Consumption of 2 CALIN+ pots per day during 16 weeks and follow up without product intake during 8 weeks.
Group B: 1 yogurt
consumption of 1 CALIN+ pot per day during 16 weeks and follow up without product during 8 weeks.
CALIN+
Consumption of 1 CALIN+ pot per day during 16 weeks and follow up without product intake during 8 weeks.
Group C: No yogurt
no changes in dietary habits during 24 weeks.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CALIN+
Consumption of 2 CALIN+ pots per day during 16 weeks and follow up without product intake during 8 weeks.
CALIN+
Consumption of 1 CALIN+ pot per day during 16 weeks and follow up without product intake during 8 weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Menopausal female subject for more than 5 years.
3. Non smoker or smoker less than 5 cigarettes a day
4. Body Mass Index (BMI) between 18 and 28 kg/m² inclusive.
5. Subject with a serum 25-hydroxyvitamin D2 + D3 between 10 and 30 ng/mL corresponding to a vitamin D insufficiency.
6. Subject with a Mini Nutritional Assessment (MNA) \> 20.
7. Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination).
8. Normal blood pressure (BP) and heart rate (HR) at the screening visit after 10 minutes in supine position:
* 95 mmHg ≤ systolic blood pressure (SBP) ≤ 160 mmHg,
* 50 mmHg ≤ diastolic blood pressure (DBP) ≤ 95 mmHg,
* 40 bpm ≤ HR (heart rate) ≤ 80 bpm.
9. Subject with normal dietary habits (no vegetarian, lactose intolerant, gluten-free subject).
10. Having given a written informed consent prior to selection.
11. Covered by Health Insurance System and / or in compliance with the recommendations of National Law in force relating to biomedical research.
Exclusion Criteria
2. Subject who consumed more than 3 dairy products per day.
3. Functional impotence.
4. Concomitant bone disease or affecting mineral metabolism, in whatever form.
5. History of bone fracture in the previous year.
6. Presence of a primary hyperparathyroidism, chronic gastrointestinal disease or patent hepatic and/or renal impairment or a progressive severe disease.
7. Type 1 diabetic subject.
8. Subject with eating disorder.
9. Subject with a treatment which can interfere with the study purpose at the moment of recruitment or 6 months before (see section 5.6)
10. Significant allergies or food intolerance.
11. Subject who cannot be contacted in case of emergency.
12. History or presence of drug or alcohol abuse (alcohol consumption \> 5 glasses / day).
13. Medical and surgical history which, in the judgment of the Investigator, is not compatible with this study.
14. Subject who, in the judgment of the Investigator, is likely to be non-compliant or uncooperative during the study, or unable to cooperate because of a language problem, or has poor mental development.
15. Blood donation within two months before the study beginning.
16. Subject in the exclusion period of a previous study or subject who refuse to be on the "Fichier National des Volontaires Sains".
17. Subject who refuse to sign the Informed Consent Form.
18. Participation to another study within 3 months prior the study beginning.
19. Subject under administrative or legal supervision.
20. Subject who are deprived of their liberty by judicial of administration decision.
21. Subject who would receive more than 4500 euros as indemnities for his participation in biomedical research within the 12 last months, including the indemnities for the present study.
55 Years
75 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eurofins Optimed
INDUSTRY
Yoplait France SAS
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mathilde Latreille-Barbier, MD
Role: PRINCIPAL_INVESTIGATOR
Eurofins Optimed
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Eurofins Optimed
Gières, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CATWIN2107
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.